Prostate cancer diagnostic test (run through CCL) now available through BMI Healthcare

 
Lab21_20190821_14-23-47.jpgTest

The Select MDx test that we run at Cambridge Clinical Laboratories is now available through BMI Healthcare. The test is a non-invasive urine test to improve patient selection for prostate cancer diagnostic biopsy and therefore will alleviate many from going through the invasive biopsy. 

 

The test, that is widely used in Europe, isn’t yet approved by NICE, so not offered in the NHS. This is a good development in increasing the accessibility of this game changing test. 

 

BMI Healthcare is the UKs largest private hospital group with 51 hospitals and clinics throughout the UK. They offer over 500 different treatments across more than 60 specialities. Find out more about BMI Healthcare www.bmihealthcare.co.uk

 

Read more about Select MDx at MDX Health.

Follow our social media feeds for more on CCL:

·      Twitter @camclinlabs 

·       LinkedIn @Cambridge Clinical Laboratories

  

 
Company news, Press release, OncologyKelly MorelCambridge Clinical LaboratoriesMDX, Prostate Cancer, BMI